Xilio Therapeutics, Inc. Insider Trading

XLO

⊜ Compare

Last 12 months

Insiders bought 44K and sold 6K on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+38K

1 buy · 2 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 2

executives and directors

Last open-market buy

Mar 2026

Mar 26, 2026

Get an email when XLO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 26	James Samuel Shannon Director	Bought	5,000	$8.79	44K	100%	Form 4
Jan 2	Kevin M. Brennan SVP, Finance and Accounting	Sold10b5-1 plan	1,826	$0.64	1K	22%	Form 4
Jan 2	Christopher James Frankenfield Chief Financial Officer	Sold10b5-1 plan	7,030	$0.64	4K	22%	Form 4
Jun 16, 2025 – Jun 17, 2025	James Samuel Shannon Director	Bought 2 parts	70,000	$0.69 average	48K	New	Form 4
Jun 16, 2025	Rene Russo President and CEO	Bought	36,289	$0.68	25K	15%	Form 4
Jan 2, 2025	Christopher James Frankenfield Chief Financial Officer	Sold10b5-1 plan	6,954	$0.98	7K	36%	Form 4
Jan 2, 2025	Kevin M. Brennan SVP, Finance and Accounting	Sold10b5-1 plan	1,803	$0.98	2K	36%	Form 4
Dec 18, 2024	Gilead Sciences, Inc. Large holder	Bought	1,759,978	$1.04	$1.83M	24%	Form 4

Mar 26
James Samuel Shannon
Director · bought 5,000 at $8.79
44K
100% of stake
Jan 210b5-1 plan
Kevin M. Brennan
SVP, Finance and Accounting · sold 1,826 at $0.64
1K
22% of stake
Jan 210b5-1 plan
Christopher James Frankenfield
Chief Financial Officer · sold 7,030 at $0.64
4K
22% of stake
Jun 16, 2025 – Jun 17, 2025
James Samuel Shannon
Director · bought 70,000 at avg $0.69
48K
New position
Jun 16, 2025
Rene Russo
President and CEO · bought 36,289 at $0.68
25K
15% of stake
Jan 2, 202510b5-1 plan
Christopher James Frankenfield
Chief Financial Officer · sold 6,954 at $0.98
7K
36% of stake
Jan 2, 202510b5-1 plan
Kevin M. Brennan
SVP, Finance and Accounting · sold 1,803 at $0.98
2K
36% of stake
Dec 18, 2024
Gilead Sciences, Inc.
Large holder · bought 1,759,978 at $1.04
$1.83M
24% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch XLO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with XLO

CompareIntrinsic value

DERMJourney Medical Corp

$4.73+1.94%25

FBIOFortress Biotech Inc.

$1.97+1.55%59

BCYCBicycle Therapeutics PLC

$3.72+1.36%40

SPROSpero Therapeutics Inc.

$1.07+2.88%63

RMTIRockwell Medical, Inc.

$8.05-0.49%37

ENTAEnanta Pharmaceuticals Inc.

$10.65+2.70%25

LXRXLexicon Pharmaceuticals, Inc.

$1.48+1.37%40

PRTAProthena Corporation plc

$8.39+2.19%25

Spot a number that looks wrong? Check it in XLO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing XLO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.